How GLP-1 Peptides Cause Weight Loss
Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases after eating. It signals your brain that you're full, slows gastric emptying (food leaves your stomach more slowly), and improves insulin sensitivity. GLP-1 receptor agonists like semaglutide and tirzepatide mimic this hormone at pharmacological doses.
The result: appetite drops significantly, portions naturally decrease, and most patients find food noise — the constant background thoughts about eating — quiets considerably. This is why average weight loss in clinical trials (12–22% of body weight) far exceeds what most patients achieve with diet and exercise alone.
The Three Main Options
Compounded Semaglutide
Same active ingredient as Ozempic (diabetes) and Wegovy (obesity). Once-weekly subcutaneous injection. Dose escalates from 0.25mg/week up to 2.4mg/week over 12–16 weeks. Average weight loss in STEP trials: 14.9% over 68 weeks. Cost: $150–300/month compounded, vs. $800–1,200/month for Ozempic without insurance.
Compounded Tirzepatide
Dual GLP-1/GIP agonist — same mechanism as Mounjaro and Zepbound. Activates two receptors instead of one. Surpass-COMBO2 trial showed 15.7% weight loss vs. 2.4% placebo; SURMOUNT-1 showed 15–22% depending on dose. Slightly more expensive than semaglutide at compounded rates. Cost: $300–700/month compounded, vs. $1,000–1,200/month for brand-name Mounjaro.
BPC-157 (Adjunctive)
Some patients incorporate BPC-157 during GLP-1 therapy for gut health support. GLP-1 medications can cause GI distress — nausea, constipation, changes in motility — during dose escalation. BPC-157's gut-protective and mucosal repair properties may help some patients tolerate the titration phase better. It is an adjunct, not a primary weight loss agent.
The Cost Comparison
| Medication | Compounded (TN) | Brand-Name (No Insurance) |
|---|---|---|
| Semaglutide | $150–300/month | $800–1,200/month (Ozempic) |
| Semaglutide (high-dose) | $200–400/month | $1,300–1,600/month (Wegovy) |
| Tirzepatide | $300–700/month | $1,000–1,200/month (Mounjaro) |
Compounded rates are estimates. See our full cost guide for current pricing including consultation and lab fees.
Who Is a Good Candidate
GLP-1 therapy is typically appropriate for adults who meet at least one of:
- BMI ≥ 30 (obesity), with or without weight-related comorbidities
- BMI ≥ 27 (overweight) with at least one condition: hypertension, type 2 diabetes, dyslipidemia, or sleep apnea
- Prior failure with diet and exercise alone over a sustained period
Not appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, Type 1 diabetes, or pregnancy. The physician intake screens for all of these.
What the Process Looks Like
No clinic visit required. Tennessee telehealth law allows new patient relationships via video or asynchronous platform.
- Complete online health intake — 10–15 minutes
- Tennessee-licensed physician reviews your intake within 1–3 business days
- Video or async consultation; physician confirms candidacy and selects protocol
- Prescription sent to compounding pharmacy partner
- Medication ships to your Tennessee address within 5–7 business days
- Monthly check-ins; dose adjustments as needed via telehealth
What to Expect in the First 90 Days
Weeks 1–4 are the titration phase. Start low (0.25mg semaglutide or equivalent), appetite suppression is noticeable but mild. Some nausea and food aversions are common. Eat smaller portions; avoid fatty meals.
By weeks 4–8, most patients have lost 3–5% of body weight. Appetite suppression is more pronounced. GI side effects usually improve.
At the 90-day mark, most patients are at a dose of 1–1.7mg semaglutide weekly and have lost 7–10% of starting weight. This is also typically when the physician assesses whether to continue escalating or maintain the current dose.